The injectable ERR agonist Slu-pp-332 is studied in parallel for its influence on mitochondrial biogenesis and oxidative metabolism, together exploring complementary effects on energy expenditure and body composition in research models
Efficient energy metabolism is essential for all tissues, particularly those with high energy demands such as the brain, skeletal muscle, and heart
Evolution of receptors for peptides similar to glucagon
This might explain the lack of pain after PRP injection in most studies, especially the ones using leukocyte poor PRP
Liraglutide has been approved for multiple indications since its initial launch in 2010: 2010: Victoza approved for adults with type 2 diabetes 2014: Brand name Saxenda approved for obesity in adults 2017: Victoza approved for reducing the risk of major adverse cardiovascular (CV) events, heart attack, stroke, and CV death in adults with type 2 diabetes and established CV disease 2019: Victoza approved for pediatric patients aged ten and over with type 2 diabetes 2020: Saxenda approved for obesity in adolescents aged 12-17 Population According to the CDC, approximately 38 million adults in the United States have diabetes (90-95% is type 2 diabetes)
